Androgen- and Estrogen-Secreting Adrenal Cancers

被引:20
作者
Cavlan, Dominic [2 ]
Bharwani, Nishat [3 ]
Grossman, Ashley [1 ]
机构
[1] Barts & London Queen Marys Sch Med & Dent, Dept Endocrinol, Ctr Endocrinol, London, England
[2] Barts & London NHS Trust, Dept Endocrinol, London, England
[3] Royal Free Hampstead, Dept Radiol, London, England
关键词
FEMINIZING ADRENOCORTICAL CARCINOMA; CORTICAL CARCINOMA; CHEMICAL-SHIFT; AROMATASE-ACTIVITY; TUMORS; FEATURES; MASSES; EXPRESSION; MITOTANE; ADENOMA;
D O I
10.1053/j.seminoncol.2010.10.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Androgen-secreting adrenal cancers are extremely rare malignancies, accounting for only a tiny proportion of the total number of women presenting with signs of androgen excess. Estrogen-secreting adrenal cancers are rarer still. Understanding how these tumors work benefits from an appreciation of adrenal steroid biosynthesis, as it is said that secretion in cancers is an anarchic version of normal adrenal function. Selection of patients in whom we should have a high suspicion of a malignancy is vital, so that biochemical investigation and imaging is deployed appropriately. When an adrenal tumor is found to secrete androgens or estrogens to excess, it can be difficult to confirm that it is a cancer, as there is significant overlap in the secretory patterns and imaging appearances of benign and malignant disease. The most reliable indicator of malignancy in these tumors remains the presence of metastases. Treatment is essentially surgical, although the role of mitotane is one undergoing evaluation. © 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:638 / 648
页数:11
相关论文
共 84 条
[1]
Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients [J].
Abiven, Gwenaelle ;
Coste, Joel ;
Groussin, Lionel ;
Anract, Philippe ;
Tissier, Frederique ;
Legmann, Paul ;
Dousset, Bertrand ;
Bertagna, Xavier ;
Bertherat, Jerome .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (07) :2650-2655
[2]
ABRAHAM GE, 1976, OBSTET GYNECOL, V47, P395
[3]
Clinical review: Adrenocortical carcinoma: Clinical update [J].
Allolio, Bruno ;
Fassnacht, Martin .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06) :2027-2037
[4]
Androgen therapy in women [J].
Arlt, W .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (01) :1-11
[5]
The prevalence and features of the polycystic ovary syndrome in an unselected population [J].
Azziz, R ;
Woods, KS ;
Reyna, R ;
Key, TJ ;
Knochenhauer, ES ;
Yildiz, BO .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2745-2749
[6]
FEMINIZING ADRENOCORTICAL CARCINOMA IN A POST-MENOPAUSAL WOMAN [J].
BARCELO, B ;
ABASCAL, J ;
ARDAIZ, J ;
GIL, P ;
COLAS, A ;
MENENDEZ, J ;
INCHAUSTI, JL .
POSTGRADUATE MEDICAL JOURNAL, 1979, 55 (644) :406-408
[7]
Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors [J].
Bencsik, Z ;
Szabolcs, I ;
Kovacs, Z ;
Ferencz, A ;
Voros, A ;
Kaszas, I ;
Bor, K ;
Gonczi, J ;
Goth, M ;
Kovacs, L ;
Dohan, O ;
Szilagyi, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05) :1726-1729
[8]
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial [J].
Berruti, A ;
Terzolo, M ;
Sperone, P ;
Pia, A ;
Della Casa, S ;
Gross, DJ ;
Carnaghi, C ;
Casali, P ;
Porpiglia, F ;
Mantero, F ;
Reimondo, G ;
Angeli, A ;
Dogliotti, L .
ENDOCRINE-RELATED CANCER, 2005, 12 (03) :657-666
[9]
Adrenal cortical carcinoma : advances in the pathophysiology and management of this malignancy [J].
Bertagna, Xavier ;
Groussin, Lionel ;
Libe, Rossella ;
Bertherat, Jerome .
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2008, 192 (01) :87-102
[10]
PURE ESTROGEN-SECRETING FEMINIZING ADRENOCORTICAL ADENOMA [J].
BHETTAY, E ;
BONNICI, F .
ARCHIVES OF DISEASE IN CHILDHOOD, 1977, 52 (03) :241-243